• Drug: Humira (adalimumab)
  • Manufacturer: AbbVie

  • Route of Administration: Subcutaneous

  • Site of Care: Outpatient

  • Approved Indication:

      • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
      • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
      • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
      • reducing signs and symptoms in adult patients with active ankylosing spondylitis
      • treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
      • treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older
      • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
      • treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older
      • treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older

  • Disease: ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis

  • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology, Immunology

  • Enrollment Form Link: www.abbvie.com/patients/patient-support

  • Phone Number: 1-800-488-6472
  • Fax Number: 1-800-783-7050
  • Product Website: humira.com